echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Vaccines, testing reagents have both skyrocketed because of the "Qingdao outbreak again"

    Vaccines, testing reagents have both skyrocketed because of the "Qingdao outbreak again"

    • Last Update: 2020-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Text . . . Cephalosporine Today, Qingdao City Health and Health Committee issued a new coronavirus pneumonia outbreak notice, as of October 11 at 23 o's time, Qingdao City found a total of 6 confirmed cases.
    qingdao has developed and started a full-time testing program, within 5 days of the city's full coverage of testing, test results will be released in a timely manner.
    , the National Health and Health Commission also sent a working group to Qingdao today to guide the local epidemic prevention and control work.
    , WHO Director-General Tan Desser said on April 22nd that the new coronary pneumonia virus would be long-term and that outbreaks could easily relapse.
    Today, the weather has just ushered in the autumn gradually cool, 55 consecutive days without the emergence of local confirmed cases of the situation was ended, two sections of retaliatory travel did not cause a sudden outbreak, but also yesterday ushered in bad news, but also on the side to prove the new crown virus "pre-cold recurrence" characteristics.
    so, to get rid of the impact of the new crown outbreak, still have to hope that the "new crown vaccine" research and development.
    morning, vaccine stocks again sucked gold on the same day, the pharmaceutical manufacturing capital market performance, as of the end of the draft, net inflows of 906 million yuan.
    And relative to individual stocks, Watson bio-sucking 339 million, located in the day's net inflow of funds first, followed by Changchun Gaoxin, Eyre ophthalmology, Daan gene, Hengrui medicine, Huada gene, has net inflow of 207 million, 159 million, 155 million, 129 million, 100 million in turn.
    It is also worth mentioning that the new crown vaccine concept of "Shandong Pharmaceutical Glass" and a series of other online red stocks, after a 174% surge, a short two-month decline of up to 44% was suppressed, today began to slowly rebound, Qingdao outbreak on the other hand to save its share price trend.
    test reagent demand increased, the surge expected according to the Beijing News on the afternoon of October 12 reported that the city of Qingdao has detected close contacts 132 people, all the implementation of centralized isolation observation, all completed nucleic acid testing, of which 9 nucleic acid test results positive, the rest are negative.
    Close contacts of 171 people, all of the implementation of centralized isolation observation, nucleic acid test results are negative, general contact 840 people, nucleic acid test results are negative, medical personnel, inpatients and escorts 162601 people, completed nucleic acid testing 154815 people, the results are negative, community testing population 114221 people, completed nucleic acid testing 75296 people, the results are negative.
    , and with the city's nucleic acid testing work continues to accelerate, it is expected that large-scale inspection work and the use of testing reagents face a significant increase, it is inevitable.
    , listed enterprises in the "new crown detection-related" enterprises are also on the trend ushered in a good.
    Take D'Angelo, for example, which was flat in early trading, but its shares rose rapidly at 14:28 p.m., closing at 39.98 yuan per share, up 9.93 percent.
    and for the entire new crown detection industry, the overall red, the market reaction is not ordinary! Some of the new crown testing reagent enterprises Dayan gene today's stock price fluctuation table people hope that the progress of the new crown vaccine research and development progress in an orderly manner for the moment, as the people look forward to the new crown vaccine, in the more force of the synergy to promote, is expected to soon enter the cash period, research and development progress fast, capacity, low cost enterprises are more likely to cash in revenue and profits, the first.
    research and development at home and abroad, the domestic inactivated vaccine and adenovirus vector vaccine technology route is the fastest progress, overseas is the mRNA vaccine and adenovirus vector vaccine technology route is the fastest progress.
    , bioNTech/Pfizer's mRNA vaccine and AstraZeneta's adenovirus vector vaccine are expected to be approved by the end of the year.
    china, inactivated vaccine and adenovirus vector vaccine technology route progress is the fastest, Wuhan Institute, Beijing Institute, Science and Technology Biology, Consino Biology overseas clinical phase III.
    have reached agreements with some countries to cooperate in the procurement of new coronavirus vaccines.
    The rest, such as Zhongsheng Group, Coxing Bio, Concino Bio, Zhifei Bio, Kantai Bio, Watson Bio, Fosun Pharma, Wantao Bio, Hualan Bio and other enterprises are also carrying out the development of new coronavirus vaccine.
    So, people expect that research and development will not unexpectedly lead the way will be the rapid progress of research and development enterprises, but in terms of production, the overall enterprise will benefit the most, it is still unknown! In addition, in conjunction with today's National Health Insurance Administration released the content: vaccination of new crown pneumonia vaccine is not included in the scope of health insurance payments.
    doesn't seem to have an impact on the business, but it also limits the factory price of vaccines to a large extent, further increasing the demand for cost control and risk estimates.
    win or lose, wait for the follow-up!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.